Follow the progress of Hemolens Diagnostics
This website contains information intended only for persons professionally dealing with medical devices (e.g. for persons performing medical professions, for persons dealing with the distribution of medical devices). Please confirm that you are a medical device professional to proceed.
Follow the progress of Hemolens Diagnostics
November 21, 2022
On 10 November at the ISPOR 2022 Europe conference, independent research company Panaxea presented the results of a study evaluating the functionality of FFR-CT versus standard diagnostics in patients with stable (continuous) chest pain in the Netherlands.
A virtual fractional flow reserve (FFR-CT) assessment developed from coronary computed tomography angiography (CCTA) could provide a non-invasive alternative to current diagnostics.
Panaxea study for Hemolens Diagnostics was aimed at was set up to assess the healthcare costs and effects of FFR-CT guided diagnostics compared to standard diagnostics for patients with stable chest pain in The Netherlands over a time period of one year. Please keep in mind that this is an early HTA (HTA – Health Technology Assessment) study, meaning that not everything is based on the best available data.
A decision tree model was developed to assess cost differences from a hospital perspective, as well as the probability of making correct diagnoses and the risk of adverse cardiovascular events. It can be noted that FFR-CT scored better in all three parameters assessed than current diagnostics over a one-year period in the Netherlands.If you look at the table you can see that the FFR-CT scored better on all three mentioned factors than the standard care within one year in The Netherlands.
In addition to this analysis, one-way sensitivity analyses were conducted to determine the main drivers of the cost difference between the strategies. It can be noted that the main drivers of the difference in costs were the probabilities and costs of revascularization and test characteristics of FFR-CT and CCTA.
At last, a threshold analysis showed that the added price of the FFR-CT analysis should be below €793 per patient to be the least costly option in this model.
To conclude, our early HTA findings suggest that FFR-CT may reduce total healthcare spending, probability of incorrect diagnosis, and risk of major adverse cardiovascular events compared to current diagnostics for patients with stable chest pain in The Netherlands. Future cost-effectiveness studies could determine value-based pricing for FFR-CT, quantify the economic value of the anticipated therapeutic impact, and decrease some of the uncertain parameters used in the early HTA study.
